Loading
JPXHealthcareBiotechnology
Latest quote
¥1,204
−¥42.00 · -3.37%
Nxera Pharma Co., Ltd., established in Tokyo, Japan, in 1990, is a biopharmaceutical enterprise focused on the discovery, development, and commercialization of pharmaceutical solutions. The company's operations extend across multiple international markets, including Japan, Switzerland, the United States, Bermuda, and the United Kingdom. Its array of commercially available products encompasses respiratory treatments like Ultibro/Breezhaler and Seebri/Breezhaler for chronic obstructive pulmonary disease, as well as Enerzair and Breezhaler to manage asthma. Other marketed therapeutics include ORAVI, a unique formulation addressing oropharyngeal candidiasis, and PIVLAZ, prescribed for cerebral vasospasm. The firm boasts a robust pipeline of investigational medicines, featuring HTL0039732 for immuno-oncology, HTL0048149 for schizophrenia, Daridorexant targeting insomnia, and HTL0016878 for both schizophrenia and other neuropsychiatric conditions. Additional compounds under development include PF-07081532 for Type 2 diabetes mellitus and obesity, PF-07054894 for inflammatory bowel disease, PF-07258669 for anorexia, and PF-06954522 for metabolic disorders. The pipeline also contains NBI-1117569 for various neurological diseases and NBI-1117570 for central nervous system ailments. Furthermore, Nxera Pharma is advancing a GPR35 agonist in the preclinical stage for inflammatory bowel disease and other gastrointestinal conditions, alongside other early-stage drug candidates. The company maintains significant strategic collaborations with industry leaders such as AbbVie, Biohaven, Genentech Inc., GSK, Pfizer Inc., Neurocrine Biosciences Inc., Novartis International AG, and Verily.
Latest quote
¥1,204
−¥42.00 · -3.37%
Regular session · JST · Market data may be delayed.
Nxera Pharma Co., Ltd., established in Tokyo, Japan, in 1990, is a biopharmaceutical enterprise focused on the discovery, development, and commercialization of pharmaceutical solutions. The company's operations extend across multiple international markets, including Japan, Switzerland, the United States, Bermuda, and the United Kingdom. Its array of commercially available products encompasses respiratory treatments like Ultibro/Breezhaler and Seebri/Breezhaler for chronic obstructive pulmonary disease, as well as Enerzair and Breezhaler to manage asthma. Other marketed therapeutics include ORAVI, a unique formulation addressing oropharyngeal candidiasis, and PIVLAZ, prescribed for cerebral vasospasm. The firm boasts a robust pipeline of investigational medicines, featuring HTL0039732 for immuno-oncology, HTL0048149 for schizophrenia, Daridorexant targeting insomnia, and HTL0016878 for both schizophrenia and other neuropsychiatric conditions. Additional compounds under development include PF-07081532 for Type 2 diabetes mellitus and obesity, PF-07054894 for inflammatory bowel disease, PF-07258669 for anorexia, and PF-06954522 for metabolic disorders. The pipeline also contains NBI-1117569 for various neurological diseases and NBI-1117570 for central nervous system ailments. Furthermore, Nxera Pharma is advancing a GPR35 agonist in the preclinical stage for inflammatory bowel disease and other gastrointestinal conditions, alongside other early-stage drug candidates. The company maintains significant strategic collaborations with industry leaders such as AbbVie, Biohaven, Genentech Inc., GSK, Pfizer Inc., Neurocrine Biosciences Inc., Novartis International AG, and Verily.
Day range
Current ¥1,204
52-week range
Current ¥1,204
Regular session · JST · Market data may be delayed.
Nxera Pharma Co., Ltd., established in Tokyo, Japan, in 1990, is a biopharmaceutical enterprise focused on the discovery, development, and commercialization of pharmaceutical solutions. The company's operations extend across multiple international markets, including Japan, Switzerland, the United States, Bermuda, and the United Kingdom. Its array of commercially available products encompasses respiratory treatments like Ultibro/Breezhaler and Seebri/Breezhaler for chronic obstructive pulmonary disease, as well as Enerzair and Breezhaler to manage asthma. Other marketed therapeutics include ORAVI, a unique formulation addressing oropharyngeal candidiasis, and PIVLAZ, prescribed for cerebral vasospasm. The firm boasts a robust pipeline of investigational medicines, featuring HTL0039732 for immuno-oncology, HTL0048149 for schizophrenia, Daridorexant targeting insomnia, and HTL0016878 for both schizophrenia and other neuropsychiatric conditions. Additional compounds under development include PF-07081532 for Type 2 diabetes mellitus and obesity, PF-07054894 for inflammatory bowel disease, PF-07258669 for anorexia, and PF-06954522 for metabolic disorders. The pipeline also contains NBI-1117569 for various neurological diseases and NBI-1117570 for central nervous system ailments. Furthermore, Nxera Pharma is advancing a GPR35 agonist in the preclinical stage for inflammatory bowel disease and other gastrointestinal conditions, alongside other early-stage drug candidates. The company maintains significant strategic collaborations with industry leaders such as AbbVie, Biohaven, Genentech Inc., GSK, Pfizer Inc., Neurocrine Biosciences Inc., Novartis International AG, and Verily.
Day range
Current ¥1,204
52-week range
Current ¥1,204
Profitability as a percentage of reported revenue.
Revenue
Operating income
Net income
| Metric (JPY) | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | 29.62B JPY | 28.84B JPY | 12.77B JPY | 15.57B JPY | 17.71B JPY |
| Cost of goods sold | 8.2B JPY | 10.71B JPY | 4.9B JPY | 1.77B JPY | 1.74B JPY |
| Gross profit | 21.42B JPY | 18.13B JPY | 7.87B JPY | 13.8B JPY | 15.98B JPY |
| Research and development | 14.47B JPY | 11.82B JPY | 10.08B JPY | 7.45B JPY | 5.93B JPY |
| Selling, general, and administrative | 15.23B JPY | 11.68B JPY | 6.85B JPY | 3.54B JPY | 3.14B JPY |
| Operating expenses | 29.69B JPY | 23.49B JPY | 16.93B JPY | 10.99B JPY | 9.07B JPY |
| Interest income | 987M JPY | 1.48B JPY | 1.23B JPY | 236M JPY | 4M JPY |
| Interest expense | 7.48B JPY | 777M JPY | 803M JPY | 715M JPY | 528M JPY |
| Depreciation and amortization | 4.37B JPY | 3.98B JPY | 2.48B JPY | 1.35B JPY | 1.28B JPY |
| Operating income | −8.27B JPY | −5.36B JPY | −9.06B JPY | 2.81B JPY | 6.91B JPY |
| Net income | −12.53B JPY | −4.84B JPY | −7.19B JPY | 382M JPY | 1.02B JPY |
Company facts updated Sep 11, 2026.
Recent quarterly results
Recent quarterly results
Funds reporting this stock among their holdings, ordered by reported position size.
iShares Core TOPIX ETF1475.T318.1M0.01%2.91T JPY0.05%¥413.5-0.48%
Vanguard Total International Stock ETFVXUS5.81M0.00%646.2B USD0.05%$86.28-1.29%
Vanguard FTSE Developed Markets ETFVEA3.79M0.00%315B USD0.03%$71.92-1.24%
Dimensional - International Small Cap ETFDFIS2.55M0.04%5.92B USD0.39%$36.87-0.99%
Vanguard FTSE All-World ex-US Small-Cap ETFVSS1.39M0.01%13.6B USD0.06%$157.42-1.31%
Schwab International Small-Cap Equity ETFSCHC1.33M0.02%5.77B USD0.06%$50.40-1.49%
Dimensional - International Core Equity 2 ETFDFIC760.16K0.00%15.49B USD0.22%$38.61-0.85%
Dimensional - International Core Equity Market ETFDFAI586.99K0.00%18.28B USD0.18%$42.38-0.81%iShares Core TOPIX ETF1475.TVanguard Total International Stock ETFVXUSVanguard FTSE Developed Markets ETFVEADimensional - International Small Cap ETFDFISVanguard FTSE All-World ex-US Small-Cap ETFVSSSchwab International Small-Cap Equity ETFSCHCDimensional - International Core Equity 2 ETFDFICDimensional - International Core Equity Market ETFDFAIAI-generated and delayed market data for informational and educational purposes only. Not investment advice.
